Interview with Trevor Millar, Advisor, NeonMind Biosciences

Hey Psychedelic Investors! For those of you following MindMed, today’s episode is based on MindMed’s press release where MMED announced their 2020 year-end Financial results.

What was covered in MindMed’s press release?
1. MMED ‘ s total assets
2. MindMed’s Net Cash Operating Activities
3.MMEDF ‘s Net loss
4. The company’s Cash on Hand
5. The date and hour for MindMed ‘s earnings call

MMED / MMEDF / MMQ ‘ stock has been experiencing a little fall lately… As long as the price doesn’t fall below $2 USD, we should still be good-ish in terms of the NASDAQ stock price requirements.. Hopefully it won’t fall below that threshold!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #MMEDNews

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

#CathieWood #ARKG #PsychedelicStocks

In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).

2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.

But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?

In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?

2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls

Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements

** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF